Market Indices
Sector Heatmap
RXRX — Recursion Pharmaceuticals, Inc. Class A Common Stock
NasdaqRecursion Pharmaceuticals, Inc. Class A Common Stock
- O
- 4.19
- H
- 4.20
- L
- 3.79
- V
- 30.73M
RXRX — Latest News & Headlines
20 StoriesRXRX Stock Quote Price and Forecast - CNN
RXRX Stock Quote Price and Forecast CNN
Recursion Pharmaceuticals Shares Jump as AI Partnership Momentum and Short-Covering Appear to Lift Sentiment - Quiver Quantitative
Recursion Pharmaceuticals Shares Jump as AI Partnership Momentum and Short-Covering Appear to Lift Sentiment Quiver Quantitative
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors Yahoo Finance
RXRX Rises As Tempus AI Deal Locks In $42M - Timothy Sykes
RXRX Rises As Tempus AI Deal Locks In $42M Timothy Sykes
RXRX Stock Rises As Tempus AI Deal Extends To 2029 - StocksToTrade
RXRX Stock Rises As Tempus AI Deal Extends To 2029 StocksToTrade
Under a trading plan, Recursion (RXRX) director sells 50,000 shares averaging $4.84 each. - Stock Titan
Under a trading plan, Recursion (RXRX) director sells 50,000 shares averaging $4.84 each. Stock Titan
What Could Go Wrong With Recursion Pharmaceuticals Stock? - Trefis
What Could Go Wrong With Recursion Pharmaceuticals Stock? Trefis
Recursion Pharmaceuticals (RXRX) Following Its Tempus AI Deal And The Valuation Debate - Simply Wall Street
Recursion Pharmaceuticals (RXRX) Following Its Tempus AI Deal And The Valuation Debate Simply Wall Street
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares - Yahoo Finance
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares Yahoo Finance
25,000 shares worth $125K are proposed for sale by Recursion (RXRX) director Robert Hershberg. - Stock Titan
25,000 shares worth $125K are proposed for sale by Recursion (RXRX) director Robert Hershberg. Stock Titan
RXRX Stock Dips As Traders Weigh Cash Runway And Heavy Losses - Timothy Sykes
RXRX Stock Dips As Traders Weigh Cash Runway And Heavy Losses Timothy Sykes
RXRX Stock Grinds Higher As Traders Focus On Runway And Range - StocksToTrade
RXRX Stock Grinds Higher As Traders Focus On Runway And Range StocksToTrade
Recursion Pharmaceuticals Stock Short Interest Falls to 34.95% - Quiver Quantitative
Recursion Pharmaceuticals Stock Short Interest Falls to 34.95% Quiver Quantitative
Could Tempus RNA License Alter The Investment Case For Recursion Pharmaceuticals (RXRX)? - Simply Wall Street
Could Tempus RNA License Alter The Investment Case For Recursion Pharmaceuticals (RXRX)? Simply Wall Street
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note Yahoo Finance
RXRX Stock Grinds Higher As Traders Study Biotech Runway - Timothy Sykes
RXRX Stock Grinds Higher As Traders Study Biotech Runway Timothy Sykes
A director sells 25,000 shares at $5 after exercising options at $2.22 at Recursion (RXRX). - Stock Titan
A director sells 25,000 shares at $5 after exercising options at $2.22 at Recursion (RXRX). Stock Titan
A $0-per-share award brings Zavain Dar's direct Recursion (RXRX) holdings to 245,371 shares. - Stock Titan
A $0-per-share award brings Zavain Dar's direct Recursion (RXRX) holdings to 245,371 shares. Stock Titan
Dean Y. Li receives 3,378 Recursion (RXRX) shares under its Outside Director Compensation Policy. - Stock Titan
Dean Y. Li receives 3,378 Recursion (RXRX) shares under its Outside Director Compensation Policy. Stock Titan
Cathie Wood’s ARK sells TWST stock, buys RXRX and NTLA - Investing.com
Cathie Wood’s ARK sells TWST stock, buys RXRX and NTLA Investing.com